Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.

Thromb Res

Departamento de Bioquímica Médica, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Cidade Universitária, Ilha do Fundão, Avenida Bauhínia 400, Rio de Janeiro, CEP-21941-590, Rio de Janeiro, Brazil.

Published: May 2005

A number of studies indicate that coagulation proteases play significant roles in cancer biology. Melanoma is a highly metastatic cancer, and there is evidence that thrombin contributes to this aggressive pattern. However, few studies correlate this type of cancer with formation of the prothrombinase complex, which is responsible for conversion of prothrombin into thrombin in the coagulation system. The aim of this study was to investigate the assembly and regulation of prothrombinase complex on the murine melanoma cell line, B16F10. B16F10 cells were unable to activate prothrombin except when previously incubated with factor Xa. This effect was dependent on factor Xa binding to cell membranes, since no activation was detected with Gla-domainless factor Xa. The thrombin formation by B16F10-bound factor Xa was enhanced approximately 10 fold in the presence of factor Va, indicating the assembly of prothrombinase complex. Differently from platelets, B16F10-assembled prothrombinase complex was inhibited by prothrombin fragment 1 but not by fragment 2. In addition, bothrojaracin, a specific ligand of proexosite I on prothrombin, caused a significant decrease in the zymogen activation. Our data demonstrate that B16F10 melanoma cells generate thrombin by promoting assembly of the prothrombinase complex. This ability might be correlated with the increased metastatic potential of this cell line. Moreover, B16F10-assembled prothrombinase complex seems to be modulated in a different way from that found for the physiological complex assembled on platelets.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2004.08.001DOI Listing

Publication Analysis

Top Keywords

prothrombinase complex
28
assembly regulation
8
regulation prothrombinase
8
complex
8
b16f10 melanoma
8
melanoma cells
8
assembly prothrombinase
8
b16f10-assembled prothrombinase
8
prothrombinase
7
factor
5

Similar Publications

Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach.

J Thromb Haemost

November 2024

Department of Mathematics, University of North Carolina at Chapel Hill, Chapel Hill, NC; Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address:

Background: Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits factor (F)Xa, the TF-FVIIa-FXa complex, and early forms of the prothrombinase complex. Concizumab is a monoclonal antibody that blocks FXa inhibition by TFPI and reduces bleeding in hemophilia.

Objectives: To examine how concizumab impacts various reactions of TFPI to restore thrombin generation in hemophilia A using mathematical models.

View Article and Find Full Text PDF

Back to basics: the coagulation pathway.

Blood Res

October 2024

Daisy Hill Hospital, 5 Hospital Road, Newry, BT35 8DR, UK.

The classic coagulation cascade model of intrinsic and extrinsic coagulation pathways, i.e. contact activation pathway and tissue factor pathway, has been widely modified.

View Article and Find Full Text PDF

Rapid and ordered cleavage of prothrombin by Hopsarin D in the absence of phospholipid membranes.

J Thromb Haemost

November 2024

Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom. Electronic address:

Background: Thrombin is produced by the prothrombinase complex, composed of factor (f)Xa and fVa on a phospholipid (PL) membrane surface. Snakes of the Elapidae family have venom versions of these factors that cause coagulopathy in prey. Group C venoms contain both fⅩa and fⅤa orthologues.

View Article and Find Full Text PDF

Kinetic analysis of prothrombinase assembly and substrate delivery mechanisms.

J Theor Biol

November 2024

Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, 30 Srednyaya Kalitnikovskaya str., Moscow 109029, Russia; National Medical Research Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, 1 Samory Mashela St, 117198 Moscow, Russia. Electronic address:

Prothrombinase complex, composed of coagulation factors Xa (FXa) and Va (FVa) is a major enzyme of the blood coagulation network that produces thrombin via activation of its inactive precursor prothrombin (FII) on the surface of phospholipid membranes. However, pathways and mechanisms of prothrombinase formation and substrate delivery are still discussed. Here we designed a novel mathematical model that considered different potential pathways of FXa or FII binding (from the membrane or from solution) and analyzed the kinetics of thrombin formation in the presence of a wide range of reactants concentrations.

View Article and Find Full Text PDF

Conformation of factor Xa in solution revealed by single-molecule spectroscopy.

J Thromb Haemost

October 2024

Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, USA. Electronic address:

Article Synopsis
  • * The research utilized single-molecule Förster resonance energy transfer to investigate the structure of FXa, revealing that it behaves similarly in free form and when bound to physiologic substrates.
  • * Results suggest major conformational changes in FXa occur when calcium is absent, indicating that vitamin K antagonists could affect its structure by disrupting the Gla domain’s interaction with calcium ions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!